VYXEOS HAS A DEMONSTRATED SAFETY PROFILE

OVERALL FREQUENCY AND SEVERITY OF ADVERSE EVENTS WAS COMPARABLE FOR VYXEOS AND CONVENTIONAL CHEMOTHERAPY¹*^†

COMMON ADVERSE REACTIONS (≥ 10% INCIDENCE IN THE VYXEOS ARM) DURING THE INDUCTION PHASE^‡

Adapted from the VYXEOS Product Monograph.

18 % (28/153) of patients treated with VYXEOS discontinued treatment due to adverse events
vs
13 % (20/151) of patients treated with conventional chemotherapy*

PATIENTS MAY REQUIRE ADDITIONAL MONITORING AS VYXEOS IS ASSOCIATED WITH PROLONGED THROMBOCYTOPENIA AND NEUTROPENIA VS CONVENTIONAL CHEMOTHERAPY^1,2*

	VYXEOS	CONVENTIONAL CHEMOTHERAPY*
Median time to recovery from thrombocytopenia (≥ 50,000/μl) after first induction for patients who had achieved CR/CRi^1,2
Median time to recovery from neutropenia (ANC value ≥ 500/µl) after first induction for patients who had achieved CR/CRi¹

Adapted from the VYXEOS Product Monograph and Lancet, et al (2018).

CRi: Complete response with incomplete platelet or neutrophil recovery

ANC: Absolute neutrophil count

*Conventional chemotherapy includes the 7+3/5+2 regimen for induction and consolidation, using cytarabine and daunorubicin.²

†High-risk AML defined as t-AML or AML-MRC.

‡Adverse reactions were graded using NCI CTCAE version 3.0.¹

References: 1. Current VYXEOS^® Product Monograph, Jazz Pharmaceuticals Canada, Inc. 2. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36:2684–2692.

VYXEOS HAS A DEMONSTRATED SAFETY PROFILE

OVERALL FREQUENCY AND SEVERITY OF ADVERSE EVENTS WAS COMPARABLE FOR VYXEOS AND CONVENTIONAL CHEMOTHERAPY1*†

OVERALL FREQUENCY AND SEVERITY OF ADVERSE EVENTS WAS COMPARABLE FOR VYXEOS AND CONVENTIONAL CHEMOTHERAPY¹*^†